Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
James Hippel, Chief Financial Officer of Bio-Techne Corporation (TECH), reported transactions on 08/15/2025. The Form 4 shows a purchase/vest of 4,010 restricted stock units or similar awards (Code M) at $0 and a disposition of 1,926 shares at $53.60 each. After these transactions the reported beneficial ownership of common stock is 129,883 shares. The filing also lists extensive derivative holdings: multiple stock option grants and restricted or performance-based stock units totaling tens of thousands of underlying shares (for example, 186,068, 167,328, 37,632 and other position sizes as detailed in Table II). The form is signed by an attorney-in-fact on behalf of Mr. Hippel.
BIO-TECHNE Corp director Amy E. Herr reported indirect equity transactions involving her significant other on 15 Aug 2025. She received grants of 932 restricted stock units and 2,735 stock options with a $53.6000 exercise price expiring 15 Aug 2035. Restricted stock unit settlements resulted in 279 common shares, with 101 shares withheld to cover tax obligations. After these transactions, her significant other holds 1,485 restricted stock units, 20,919 stock options, and 2,154 common shares, while she also holds options on 2,415 shares and 1,040 common shares directly.
Kim Kelderman, CEO and Director of Bio-Techne Corp (TECH), reported multiple equity transactions dated 08/15/2025. The filing shows a grant/award of 8,543 restricted stock units and an acquisition of 35,354 restricted stock units and 70,708 performance restricted stock units (all reported as acquisitions at $0), plus an acquisition of 90,441 stock options exercisable at $53.60 with an 08/15/2035 expiration.
The report also discloses a sale of 4,305 shares of common stock at $53.60 and a prior acquisition of 8,543 shares (code M) resulting in 55,273 shares beneficially owned after the transactions. Numerous outstanding stock options and performance awards with varying exercise prices and vesting/expiration schedules are listed.
Shane Bohnen, SVP – General Counsel of Bio-Techne Corp (TECH), reported multiple option exercises, restricted stock unit vesting events and a small sale on 08/15/2025. The Form 4 shows a non-derivative acquisition of 1,718 shares (transaction code M) at $0 and a sale of 527 shares at $53.60, leaving 4,385 shares beneficially owned after the sale. The filing details many derivative holdings: several stock options exercisable at strike prices from $47.60 to $120.46, totaling tens of thousands of underlying shares, plus multiple restricted stock unit and performance award pools. Notable items include exercises or acquisitions that increased holdings by large blocks of shares via option-related transactions and performance awards that vest on future dates if goals are met.
Matthew McManus, President – Diag & Spatial Bio at Bio-Techne Corp (TECH), reported transactions dated 08/15/2025. He was granted 2,637 restricted stock units (non-derivative, code M) at $0 and reported a sale/disposition of 880 shares at $53.60 (code F), leaving 4,735 shares owned after the sale. The filing lists numerous derivative holdings and awards including performance restricted stock units, restricted stock units and stock options with exercise prices of $68.54, $74.91 and $53.60. Aggregate derivative positions include named totals such as 24,614, 21,320, 19,243, 15,902, 15,825, and 9,241 underlying shares across options and RSUs, with vesting schedules and performance-based vesting dates listed through 2035. The form is signed by Andrew Nick as attorney-in-fact dated 08/19/2025.
Bio-Techne Corp. (TECH) insider William Geist reported multiple equity transactions on 08/15/2025 reflecting compensation vesting and a small sale. The filing shows the acquisition of 2,623 common shares via vested restricted stock units at $0, and a disposition of 803 shares sold at $53.60, leaving 15,112 shares beneficially owned after the sale. The report also lists numerous outstanding stock options and performance-based awards, including 24,758 newly acquired stock options exercisable at $53.60 with an 08/15/2035 expiration, other options at strike prices from $74.91 to $100.39, and several restricted and performance RSU pools totaling tens of thousands of shares that vest on various future dates if conditions are met. Transactions were signed by an attorney-in-fact on 08/19/2025.
Bio-Techne Corp is reported to have a material passive investor position: T. Rowe Price Associates, Inc. discloses beneficial ownership of 8,848,150 shares of common stock, representing 5.6% of the class. The filing shows sole voting power for 8,375,015 shares and sole dispositive power for 8,732,036 shares, with no shared voting or dispositive powers. In plain terms, T. Rowe Price can vote and direct the sale of most of these shares without sharing those rights.
T. Rowe Price identifies itself as an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing does not report group affiliations or additional transactions in this statement.
John L. Higgins, a director of Bio-Techne (TECH), reported exercising stock options to acquire 5,040 shares of common stock on 08/07/2025 at an exercise price of $21.84 per share. After that transaction his reported beneficial ownership of common stock is 65,236 shares. The Form 4 lists a series of outstanding stock options held by Higgins with varying exercise prices ($21.84 to $128.81) and expiration dates ranging through 10/24/2034.
The filing also includes a disclosure that a grant made 10/24/2024 vests on the earlier of the one‑year anniversary of the grant or Bio‑Techne's 2025 annual meeting of shareholders. The form was signed by an attorney‑in‑fact acting on Higgins' behalf.